Answers are grounded in this paper and cite their sources.
Prostatic fibrosis is an important contributor to the progression and clinical manifestations of benign prostatic hyperplasia (BPH), whereas the underlying molecular mechanisms remain incompletely understood. In this study, integrative multi‐omics analyses, including RNA sequencing, proteomics, and phosphoproteomics, identified p21‐activated kinase 1 (PAK1) as a key regulator associated with prostatic fibrosis. PAK1 expression was markedly increased and was closely associated with the progression of prostatic fibrosis and BPH. Transcriptomic analyses further indicated that the profibrotic effects of PAK1 were closely related to activation of the TGF‐β signaling pathway. Functional experiments demonstrated that PAK1 promoted fibrosis‐related phenotypes and enhanced TGF‐β1 expression. Mechanistically, PAK1‐induced phosphorylation of histone deacetylase 1 (HDAC1) was associated with reduced SP1 acetylation and enhanced SP1‐dependent transcriptional activity, thereby facilitating TGF‐β1 transcription. In vivo, both genetic silencing of PAK1 and pharmacological inhibition with IPA‐3 alleviated prostatic fibrosis and attenuated BPH‐associated pathological changes. Collectively, these findings support a model in which PAK1 contributes to prostatic fibrosis and BPH progression through modulation of the HDAC1/SP1/TGF‐β1 signaling axis and suggest that PAK1 may represent a potential therapeutic target for BPH.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: